Milk-derived phospholipid supplement for adults with mild cognitive impairment
Tests a dairy milk extract supplement for thinking skills and safety in mild cognitive impairment.
Key facts
- Who runs it
- Pusan National University Yangsan Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Phospholipid-rich Dairy Extract for Cognitive Function
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 7 Jan 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Phospholipid-rich dairy milk extract
- Placebo
- Record updated
- 12 June 2025
Who can take part
The trial is looking for adults aged 55 to 85 with mild memory problems but no dementia. It tests whether a dairy milk extract rich in phospholipids (a type of fat) improves thinking and memory.
- Age
- 55 to 85 years
- Sex
- All sexes
- Disease stage
- Mild cognitive impairment: Global Deterioration Scale (GDS) score of 2-3. This means memory complaints without test evidence, or mild memory problems shown on tests. No dementia.
- Earlier treatment
- Cannot join if, in the past month, you used drugs or health functional foods that may affect thinking, such as antipsychotics, cognitive enhancers, tricyclic antidepressants or hormone replacement therapy.
- Main reasons for not taking part
- Dementia, Parkinson's disease, cerebral infarction (stroke) or other conditions linked to memory decline
- Severe stroke, heart disease or cancer in the past 6 months (stable heart or stroke history may be allowed)
- Uncontrolled blood pressure (≥160/100 mmHg) or fasting blood glucose ≥160 mg/dL (8.9 mmol/L) in people with diabetes
- Kidney or liver problems: serum creatinine, AST or ALT ≥2 times the upper limit of normal
- Alcohol abuse, allergy to the study product, or another drug trial in the past month; must be able to read Korean
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Age: Adults aged 55-85 years (inclusive), both male and female
- Global Deterioration Scale (GDS) score of 2-3:; GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment
- Absence of dementia according to established diagnostic criteria
- Ability to read Korean
Who cannot take part
- Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism
- Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period
- Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)
- Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160/100 mmHg (measured after 10 minutes of rest)
- Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities
- Food allergies: Known allergic reactions to study product components
- Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator
- Poor glycemic control: Fasting blood glucose ≥160 mg/dL in diabetic patients
- Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution
- Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution
- Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress
- Alcohol abuse
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Cognitive function or cognitive decline
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to determine whether dietary phospholipid-rich dairy milk extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.
Read full original descriptionShow less
The main questions are:
* Does dietary phospholipid-rich dairy milk extract improve cognitive function in participants? * What side effects occur when participants take phospholipid-rich dairy milk extract?
The 2 groups in the trial
- Milk groupTreatment being tested
This group takes dietary phospholipid-rich dairy milk extract for 12 weeks.
Treatment: Phospholipid-rich dairy milk extract
- Placebo groupPlacebo, for comparison
This group takes placebo for 12 weeks.
Treatment: Placebo
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Dietary Phospholipid-rich Dairy Milk Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment.
- Plain-language title
- Milk-derived phospholipid supplement for adults with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07011680, who can take part
- Record updated
- 12 June 2025